2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-114424A
    H-Ile-Pro-Pro-OH hydrochloride 1208862-61-6 98.48%
    H-Ile-Pro-Pro-OH hydrochloride, a milk-derived peptide, inhibits angiotensin-converting enzyme (ACE) with an IC50 of 5 μM. Antihypertensive tripeptides.
    H-Ile-Pro-Pro-OH hydrochloride
  • HY-116294A
    Methoctramine tetrahydrochloride 104807-46-7
    Methoctramine tetrahydrochloride is a potent and cardioselectivity antagonist of M2 muscarinic receptor. Methoctramine tetrahydrochloride can inhibit Muscarine-induced bradycardia in vivo.
    Methoctramine tetrahydrochloride
  • HY-119541A
    Ampreloxetine TFA 1227056-85-0 98.30%
    Ampreloxetine (TD-9855) TFA is a potent and orally active norepinephrine (NE) and serotonin 5-HT inhibitor. Ampreloxetine TFA has the potential for the research of neurogenic orthostatic hypotension.
    Ampreloxetine TFA
  • HY-145564A
    Emprumapimod hydrochloride ≥98.0%
    Emprumapimod (PF-07265803) hydrochloride is an orally active and selective inhibitor of p38α MAPK. Emprumapimod hydrochloride can be used for the research of dilated cardiomyopathy and acute inflammatory pain.
    Emprumapimod hydrochloride
  • HY-153491A
    Olezarsen sodium 2298451-31-5
    Olezarsen sodium is an N-acetyl-galactosamine-conjugated antisense oligonucleotide targeted to hepatic APOC3 mRNA to inhibit apolipoprotein C-III (apoC-III) production, in lowering triglyceride levels in patients at high risk for or with established cardiovascular disease.
    Olezarsen sodium
  • HY-153492A
    Olpasiran sodium 98.82%
    Olpasiran sodium is a small interfering RNA that reduces lipoprotein(a) synthesis in the liver.
    Olpasiran sodium
  • HY-153999A
    BT200 sodium 98.20%
    BT200 sodium, a pegylated form of the aptamer BT100, inhibits binding of von Willebrand factor (VWF) to platelet glycoprotein GPIb, preventing arterial thrombosis.
    BT200 sodium
  • HY-158024A
    (S)-NDT-19795 98%
    (S)-NDT-19795 is a potent NLRP3 inflammasome inhibitor. (S)-NDT-19795 blocks NLRP3 activation by inhibiting NLRP3 ATPase activity, thereby reducing the levels of pro-inflammatory cytokines IL-1β and IL-18. (S)-NDT-19795 can be used in the study of neurodegenerative diseases, cardiovascular diseases, metabolic diseases, and autoimmune diseases.
    (S)-NDT-19795
  • HY-B0205S1
    Candesartan-d5 1189650-58-5
    Candesartan-d5 is the deuterium labeled Candesartan. Candesartan is an angiotensin II receptor antagonist with IC50 of 0.26 nM.
    Candesartan-d5
  • HY-B0231AS
    Enalaprilat-d5 349554-00-3 ≥99.0%
    Enalaprilat-d5 is the deuterium labeled Enalaprilat(MK-422), which is an angiotensin-converting enzyme (ACE) inhibitor.
    Enalaprilat-d5
  • HY-B0252S1
    Hydrochlorothiazid-13C,d2 1190006-03-1 98.64%
    Hydrochlorothiazid-13C,d2 is the 13C- and deuterium labeled Hydrochlorothiazide. Hydrochlorothiazide (HCTZ), an orally active diuretic agent of the thiazide class, inhibits transforming TGF-β/Smad signaling pathway. Hydrochlorothiazide has direct vascular relaxant effects via opening of the calcium-activated potassium (KCA) channel. Hydrochlorothiazide improves cardiac function, reduces fibrosis and has antihypertensive effect.
    Hydrochlorothiazid-13C,d2
  • HY-B0309S2
    Felodipine-d3 1219795-30-8 98.10%
    Felodipine-d3 is the deuterium labeled Felodipine. Felodipine, a dihydropyridine, is a potent, vasoselective calcium channel antagonist. Felodipine lowers blood pressure (BP) by selective action on vascular smooth muscle, especially in the resistance vessels. Felodipine, an anti-hypertensive agent, induces autophagy. Felodipine can cross the blood-brain barrier.
    Felodipine-d3
  • HY-I0400S3
    N-Acetylneuraminic acid-13C-3 ≥99.0%
    N-Acetylneuraminic acid-13C-3 is the 13C labeled N-Acetylneuraminic acid.
    N-Acetylneuraminic acid-13C-3
  • HY-N0470S4
    L-Lysine-d8 hydrochloride 344298-93-7 99.88%
    L-Lysine-d8 (hydrochloride) is the deuterium labeled L-Lysine hydrochloride. L-lysine hydrochloride is an essential amino acid for humans with various benefits including treating herpes, increasing calcium absorption, reducing diabetes-related illnesses and improving gut health.
    L-Lysine-d8 hydrochloride
  • HY-W010710
    IPrAuCl 852445-83-1 98%
    IPrAuCl (compound 3) is a gold compound. IPrAuCl inhibits sarcoplasmic reticulum Ca2+-ATPase (IC50=16.3 µM).
    IPrAuCl
  • HY-W013989
    1,3-Dicyclohexylurea 2387-23-7
    1,3-Dicyclohexylurea (DCU) is an orally active and potent sEH (soluble epoxide hydrolase) inhibitor. Oral Delivery of 1,3-Dicyclohexylurea nanosuspension enhances exposure and lowers blood pressure in hypertensive Rats.
    1,3-Dicyclohexylurea
  • HY-W019726
    Dehydro Nifedipine 67035-22-7 99.84%
    Dehydro nifedipine (BAY-b 4759) is a metabolite of Nifedipine (HY-B0284). Nifedipine (BAY-a-1040) is a potent calcium channel blocker and an agent of choice for cardiac insufficiencies.
    Dehydro Nifedipine
  • HY-W021162
    Guanylate cyclase-IN-1 1361569-23-4 ≥99.0%
    Guanylate cyclase-IN-1 (Example 46) is a guanylate cyclase inhibitor that can be used for cardiovascular diseases research.
    Guanylate cyclase-IN-1
  • HY-W062836
    BAY 41-8543 256498-66-5 99.94%
    BAY 41-8543 is an orally active, nitric oxide (NO)-independent stimulator of soluble guanylyl cyclase (sGC). BAY 41-8543 has vasodilator activity in the pulmonary and systemic vascular beds in the rat. BAY 41-8543 has antiplatelet effects and has the potential for cardiovascular diseases research.
    BAY 41-8543
  • HY-W101419
    Ibuprofenamide 59512-17-3 98%
    Ibuprofenamide (Compound 136) is a potent microsomal epoxide hydrolase (mEH) inhibitor with an IC50 value of 96 μM. Ibuprofenamide is promising for research of preeclampsia, hypercholanemia and cancer.
    Ibuprofenamide
Cat. No. Product Name / Synonyms Application Reactivity